Hepatitis C

Also known as: chronic hepatitis C · HCV

Also relevant to Infectious Disease

Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.

United StatesACG/AGA/AASLD

Current

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

AASLD / IDSA · 2026 · Continuously updated web guidance

A living, web-based guidance document jointly maintained by AASLD and IDSA covering testing, treatment and management of hepatitis C, revised on an ongoing basis as evidence changes.

Recommendations are organised by patient profile, prior treatment status and special populations rather than as a single linear document. source
The site notes ongoing revisions, including a hepatitis C point-of-care test-and-treat algorithm added in 2026. source

Verify against original ↗

EuropeUEG/EASL

Current

EASL recommendations on treatment of hepatitis C: Final update of the series

EASL (European Association for the Study of the Liver) · 2020 · 2020 (final update of the series)

EASL's recommendations describe optimal management of patients with recently acquired and chronic HCV infection from 2020 onward, labelled the final update of this recommendation series.

The document covers screening and diagnosis, assessment of liver disease severity before therapy, and antiviral treatment selection. source
It frames its recommendations in the context of the WHO goal of eliminating hepatitis C as a public health threat. source

Verify against original ↗

US vs EU key differences

Update model differs fundamentally: the US AASLD/IDSA document is a continuously updated web-based living guidance, whereas the 2020 EASL recommendations were published explicitly as the final update of that series. source
Screening strategy differs: AASLD/IDSA endorses one-time opt-out HCV testing for all adults aged 18 and older, while EASL keeps a risk-based approach and treats birth-cohort or general-population screening as something to justify on local epidemiology and cost-effectiveness. source
Because the European document has not been refreshed since 2020, newer US positions such as expanded eligibility for the simplified treatment algorithm with minimal monitoring have no European counterpart. source

What changed recently

EU2018 → 2020 (final update of the series)2020-09-01
This edition supersedes the 2018 EASL recommendations and is declared the last of the series, reflecting how standardised DAA therapy has become. It endorses simplified treatment with pangenotypic sofosbuvir/velpatasvir or glecaprevir/pibrentasvir without genotyping in eligible patients, using non-invasive fibrosis assessment rather than biopsy before therapy.
source ↗curation confidence 80%

See the full update feed for changes across every system.